Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
Whatever the consensus opinion may be, our team at StockStory cuts through the noise by conducting independent analysis to determine a company’s long-term prospects. Keeping that in mind, here are three stocks facing legitimate challenges and some alternatives worth exploring instead.
MarineMax (HZO)
Consensus Price Target: $36.86 (4.5% implied return)
Appropriately headquartered in Clearwater, Florida, MarineMax (NYSE: HZO) sells boats, yachts, and other marine products.
Why Are We Out on HZO?
- Disappointing same-store sales over the past two years show customers aren’t responding well to its product selection and store experience
- Falling earnings per share over the last three years has some investors worried as stock prices ultimately follow EPS over the long term
MarineMax is trading at $35.27 per share, or 33.7x forward P/E. To fully understand why you should be careful with HZO, check out our full research report (it’s free).
Smith & Wesson (SWBI)
Consensus Price Target: $17.25 (12.7% implied return)
With a history dating back to 1852, Smith & Wesson (NASDAQ: SWBI) is a firearms manufacturer known for its handguns and rifles.
Why Should You Sell SWBI?
- Annual sales declines of 13.1% for the past five years show its products and services struggled to connect with the market
- Ability to fund investments or reward shareholders with increased buybacks or dividends is restricted by its weak free cash flow margin of 6.2% for the last two years
- Shrinking returns on capital from an already weak position reveal that neither previous nor ongoing investments are yielding the desired results
Smith & Wesson’s stock price of $15.30 implies a valuation ratio of 31.8x forward P/E. If you’re considering SWBI for your portfolio, see our FREE research report to learn more.
Zimmer Biomet (ZBH)
Consensus Price Target: $98.60 (6.1% implied return)
With a history dating back to 1927 and a presence in over 100 countries worldwide, Zimmer Biomet (NYSE: ZBH) designs and manufactures orthopedic products including knee and hip replacements, surgical tools, and robotic technologies for joint reconstruction and spine surgeries.
Why Does ZBH Give Us Pause?
- Sales trends were unexciting over the last five years as its 5.6% annual growth was below the typical healthcare company
- Estimated sales growth of 2.5% for the next 12 months implies demand will slow from its two-year trend
- Below-average returns on capital indicate management struggled to find compelling investment opportunities
At $92.89 per share, Zimmer Biomet trades at 10.6x forward P/E. Check out our free in-depth research report to learn more about why ZBH doesn’t pass our bar.
Stocks We Like More
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
